NCT05992935 - Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1403 and mRNA-1405 to Prevent Norovirus Acute Gastroenteritis in Healthy Adults 18 to 80 Years of Age | Biotech Hunter

Enrollment

1,285

Participants

Timeline

Start Date

August 25, 2023

Primary Completion Date

April 14, 2026

Study Completion Date

November 20, 2026

Conditions

Norovirus Acute Gastroenteritis

Interventions

BIOLOGICAL

mRNA-1403

Sterile liquid for injection

BIOLOGICAL

mRNA-1405

Sterile liquid for injection

BIOLOGICAL

Placebo

0.9% sodium chloride (normal saline) injection

Trial Locations (14)

14609

Rochester Clinical Research, Inc, Rochester

20854

Velocity Clinical Research, Rockville

30030

Accel Research Sites Network, Decatur

33024

Research Centers of America, Hollywood

51106

Velocity Clinical Research, Sioux City

61614

Optimal Research, Peoria

66219

Johnson County Clin-Trials (JCCT), Lenexa

68134

Velocity Clinical Research, Omaha

68701

Velocity Clinical Research, Norfolk

75154

Epic Medical Research, LLC, Red Oak

80501

Tekton Research, Inc - Longmont Center, Longmont

83642

Velocity Clinical Research - Boise, Meridian

84107

JBR Clinical Research, Salt Lake City

90815

ARK Clinical Research, LLC, Long Beach

All Listed Sponsors

lead

ModernaTX, Inc.

INDUSTRY